查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008820

青光眼治療市場報告：按藥物類別、適應症、最終用戶和地區分類（2026-2034 年）

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年全球青光眼治療市場規模達88億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到144億美元，2026年至2034年的複合年成長率（CAGR）為5.29%。北美目前引領市場，這得益於其先進的醫療基礎設施、不斷提高的青光眼防治意識、尖端治療手段的普及、強力的監管支持以及龐大的青光眼高風險老年人口。此外，全球青光眼盛行率的上升、早期診斷技術的不斷進步、眼科遠距遠端醫療的日益普及以及手術技術的許多創新也推動了市場成長。

市場規模及預測：

  • 2025年，青光眼治療市場價值將達88億美元。
  • 預計從 2026 年到 2034 年，該產業將以 5.29% 的複合年成長率成長，到 2034 年達到 144 億美元。

主要部分：

  • 藥物分類：前列腺素類似物因其顯著的降眼壓效果、每日一次給藥的便利性以及副作用少，佔據了最大的市場佔有率。這些藥物是治療方法開放性青光眼的主要藥物，因此在臨床實踐中被頻繁處方和優先選擇。
  • 適應症：開放性青光眼因其高發病率、進展緩慢以及常無症狀等特點，佔據了市場主導地位。它佔青光眼病例的大多數，也是醫療機構診斷、治療和持續管理的主要重點。
  • 終端用戶：醫院是最大的用戶群體，這得益於其先進的基礎設施、專業的醫務人員以及豐富的青光眼治療方案。醫院提供包括手術和雷射治療在內的多種治療方法，使其成為需要重症監護患者的首選。
  • 區域：北美憑藉其先進的醫療保健體系、強大的研發能力、高昂的醫療保健支出、老年人群中不斷上升的青光眼發病率以及尖端治療方法的廣泛普及，在市場中佔據主導地位。此外，監管支持和成熟製藥公司的存在也促進了市場成長。

主要企業：

  • 青光眼治療市場的主要企業包括 Aerie Pharmaceuticals Inc.、Allergan Plc、Bausch & Lomb Incorporated（Bausch Health Companies Inc.）、Inotek Pharmaceuticals Corp.、Merck & Co. Inc.、Novartis AG、Pfizer Inc.、Santen Pharmacetical.、Merck & Co. Inc.、Novartis AG、Pfizer Inc.、Santen Pharmacetical Co. 和 Ltd.、SIFI.A.

市場成長的主要促進因素：

  • 手術創新：手術技術的進步，特別是微創青光眼手術（MIGS）的進步，正在改變青光眼治療市場。 MIGS 手術更安全，併發症更少，恢復時間更短。手術器械的創新，例如微支架和引流系統，提高了手術效率，從而改善了患者的治療效果並促進了市場成長。
  • 學名藥的日益普及：學名藥的日益普及提高了患者獲得經濟實惠治療的機會。常用藥物的非專利藥提供了一種低成本、有效的替代方案，使青光眼治療更加便捷，尤其對經濟困難的患者更是如此。
  • 青光眼基因治療創新：基因治療的進步為青光眼的根本原因提供了直接治療的創新方法。這些治療方法著重於保護視網膜神經節細胞、改善粒線體功能和降低眼內壓，具有良好的長期療效和更少的副作用，使其成為傳統治療方法的理想替代方案。
  • 人口老化：隨著世界人口老化，青光眼的盛行率不斷上升，因為老年人更容易患上這種疾病。這種人口結構的變化推動了對有效診斷、治療和長期管理策略的需求，並促使人們增加對不同年齡層的治療方案的投資。
  • 提高公眾意識：意識提升對市場成長至關重要，因為它可以鼓勵人們透過定期眼科檢查進行早期發現。透過健康宣傳宣傳活動和便利的資訊取得管道提高公眾認知度，正在推動對診斷、治療和手術的需求，促進預防性醫療保健，並提高有效青光眼治療方法的可近性。
  • 藥物傳遞系統的進步：諸如緩釋植入、淚小管栓塞和注射劑等創新藥物輸送系統，與傳統眼藥水相比，能夠提供更持久的療效，從而徹底改變青光眼的治療方式。這些進步提高了患者的依從性，改善了治療舒適度，並確保了治療效果的穩定性，進而推動了對更先進、更有效的青光眼治療方法的需求。

未來展望：

  • 強勁成長前景：由於青光眼盛行率上升、人口老化、公眾意識增強以及治療方案的進步，青光眼治療市場正經歷強勁成長。創新藥物療法、微創手術和診斷技術的改進正在推動市場擴張，並為患者提供更多有效治療的機會。
  • 市場演變：隨著藥物配方、微創手術和個人化治療的進步，青光眼治療市場正在不斷發展。對神經保護和聯合治療的研究不斷深入，以及對早期檢測日益重視，將塑造未來的市場格局，為患者提供更有效、更個人化的解決方案。

青光眼是全球永久性失明的主要原因之一，每年確診人數都在增加。由於疾病通常進展緩慢且無症狀，早期發現較為困難，需要持續治療和照護的患者人數也不斷增加。因此，青光眼治療市場也不斷擴大。此外，大眾對青光眼的認知不斷提高，相關教育也得到加強，促使更多人接受篩檢，從而實現早期發現。早期療育意味著患者在視神經受到嚴重損害之前努力控制病情，這增加了對治療方法的需求，並推動了市場成長。此外，製藥公司和醫療機構加強對研究活動的投入，促使人們發現新的治療方法，包括專注於維護視神經健康的神經保護療法。這種對創新的重視正在拓展治療選擇，豐富市場上的產品種類，並為患者帶來有效控制青光眼的希望。

青光眼治療市場的趨勢與促進因素：

外科技術的進步

外科技術的進步，特別是微創青光眼手術（MIGS）的出現，正在影響青光眼治療市場。與傳統手術相比，MIGS 提供了一種更安全、併發症更少、恢復時間更短、手術更簡便的替代方案，從而徹底改變了青光眼的治療方式。這項進步為外科醫生提供了更多治療選擇，同時降低了患者的風險和不適感。此外，包括微支架和創新引流系統在內的手術器械的研發，也提高了青光眼手術的有效性。愛爾康公司計劃於 2025 年在美國推出的 Voyager™ DSLT 就是這項創新技術的傑出代表。它是世界上首個全自動直接選擇性雷射小梁小梁網整型術（DSLT）系統。該系統無需使用房角鏡或手動瞄準，即可發射 120 次雷射脈衝，從而簡化了 SLT 手術流程，提高了手術精度，並最大限度地降低了手術複雜性。這些技術創新正在增強人們對手術的信心，推動市場擴張，並改善治療效果。

學名藥的擴張

隨著學名藥的普及，獲得經濟有效治療的機會也隨之增加。一些知名青光眼藥物，例如前列腺素學名藥，其學名藥在保持療效的同時，為患者提供了比品牌藥更經濟的選擇。這一趨勢對於擴大治療覆蓋範圍至關重要，尤其對於那些可能面臨經濟困難或醫療覆蓋範圍有限的患者而言。學名藥有助於降低醫療成本，同時使更多患者能夠獲得有效的青光眼治療。隨著越來越多的製藥公司推出知名藥物的非專利藥，市場競爭日益激烈，從而降低了價格並擴大了市場准入。 2024年，美國Glenmark Pharmaceuticals公司推出了Travatan Z（0.004%曲伏前列素眼藥水）的學名藥，該藥用於治療青光眼和眼高壓。本產品與山德士公司的原廠藥具有生物等效性，進一步豐富了Glenmark的眼科藥物產品組合。截至 2024 年 9 月，Travatan Z 在美國的年銷售額為 6,620 萬美元。

基因治療的進展

基因療法的最新進展為治療青光眼提供了新穎獨特的方法。科學家正在研究旨在解決青光眼根本原因的基因療法，例如保護視網膜神經節細胞和改善粒線體功能。這些治療方法透過將特定基因導入眼內，旨在降低眼內壓，同時保護視神經健康並改善視覺相關細胞的整體功能。隨著基因療法在臨床試驗中不斷推進，這種治療方法正逐漸成為傳統治療方法的強大替代方案，有望提供更持久的療效並減少副作用。這些先進治療方法的研發吸引了大量投資和關注，並透過為患者提供更精準、更有效的青光眼治療選擇，推動了市場擴張。 2024年，都柏林聖三一學院的研究人員宣布了一項突破性的青光眼基因療法，該療法能夠保護視網膜神經節細胞並增強粒線體功能。這項治療方法利用腺相關病毒（AAV）導入eNdi1基因，並在動物和人體模型中改善了視覺相關細胞的功能。為了推進該療法進入臨床試驗階段，一家名為 Vzarii Therapeutics 的衍生公司應運而生。

青光眼治療市場成長要素：

老年人口增加

在全球範圍內，老年人口的成長，尤其是在已開發國家和快速發展中國家，正導致青光眼患者數量顯著增加。世界衛生組織（世衛組織）估計，到2030年，全球六分之一的人口將超過60歲，預計到2050年，數字將翻倍，達到21億。這種人口結構的變化增加了青光眼的高風險族群，也使得對有效的診斷方法、治療方法方案和持續管理方法的需求日益成長。老年人更容易患上青光眼等慢性疾病，並且通常需要持續治療以防止視力障礙。因此，人口老化推動了對新治療方法的需求，包括藥物療法和手術治療。這一趨勢刺激了對研發活動的投資，以開發滿足老年患者獨特需求的個人化治療方法，進一步促進了市場成長。

提高意識和早期診斷

意識提升對於推動青光眼治療市場的擴張至關重要。健康宣傳宣傳活動、眼科診所的各項措施以及資訊取得管道的改善，都在促進人們對青光眼的認知不斷提高。隨著越來越多的人意識到早期發現的重要性，定期眼科檢查的需求也在不斷成長，尤其是在高風險族群中。早期診斷能夠實現及時干預，降低不可逆性視力喪失的風險，並確保更好的治療效果。 2024年，艾伯維印度公司和印度視力保護協會共同發起了一項為期15個月的宣傳活動，旨在意識提升。該活動包括篩檢營、線上宣傳活動和教育項目，以促進早期診斷和治療。這種向預防性醫療保健的轉變正在增加對青光眼治療、診斷工具和手術方案的需求。因此，公眾認知度的提高直接促進了青光眼治療方法的普及。

藥物輸送系統的進展

緩釋植入、淚小管栓塞和注射劑等創新技術正在改變青光眼的治療方式。這些創新系統比需要定期使用的傳統眼藥水療效更持久，解決了患者依從性差的常見問題。例如，緩釋系統可在數週至數月內持續釋放藥物，最大限度地減少每日用藥的需求，從而提高治療依從性。這不僅能提升患者的舒適度，還能確保治療效果的穩定性，最終也能改善眼壓控制的品質。人們對改善藥物輸送系統的興趣日益濃厚，推動了對更先進的青光眼治療方法的需求。 2024年，Ripple Therapeutics宣布與艾伯維（AbbVie）合作開發RTC-620，這是一種完全可生物分解的緩釋前房植入，用於降低青光眼患者的眼壓。 Ripple將負責臨床前開發，而艾伯維將主導臨床試驗和商業化。該植入無需使用聚合物或添加劑即可重複給藥，降低了發炎風險。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球青光眼治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 前列腺素類似物
  • BETA阻斷劑
  • α腎上腺素促效劑
  • 碳酸酐酶抑制劑
  • 組合藥物
  • 其他

第7章 市場區隔：依適應症分類

  • 開放性青光眼
  • 隅角閉鎖性青光眼
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 眼科診所
  • 門診手術中心
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated（Bausch Health Companies Inc.）
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI SpA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A2770

The global glaucoma therapeutics market size reached USD 8.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 14.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.29% during 2026-2034. North America currently leads the market because of advanced healthcare infrastructure, increasing awareness, access to cutting-edge treatments, strong regulatory support, and a large aging population at risk for glaucoma. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Market Size & Forecasts:

  • Glaucoma therapeutics market was valued at USD 8.8 Billion in 2025.
  • The market is projected to reach USD 14.4 Billion by 2034, at a CAGR of 5.29% from 2026-2034.

Dominant Segments:

  • Drug Class: Prostaglandin analogs hold the biggest market share attributed to their effectiveness in lowering intraocular pressure, the convenience of once-daily dosing, and few side effects. These drugs are the primary therapy for open-angle glaucoma, leading to their frequent prescription and preference in clinical settings.
  • Indication: Open angle glaucoma dominates the market due to its high prevalence, gradual progression, and frequently asymptomatic characteristic. It represents the largest portion of glaucoma instances, establishing it as the main emphasis for diagnosis, treatment, and ongoing management within healthcare.
  • End User: Hospitals represent the largest segment because of their sophisticated infrastructure, expert medical personnel, and extensive treatment alternatives for glaucoma. They provide a variety of therapies, such as surgeries and laser treatments, making them the main option for patients needing intensive care.
  • Region: North America dominates the market owing to its sophisticated healthcare systems, robust research and development (R&D) abilities, substantial healthcare expenditure, rising glaucoma incidence among the elderly, and extensive availability of cutting-edge treatments. Moreover, regulatory assistance and established pharmaceutical firms contribute to the market growth.

Key Players:

  • The leading companies in glaucoma therapeutics market include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Inotek Pharmaceuticals Corp., Merck & Co. Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co. Ltd., SIFI S.p.A, and Teva Pharmaceutical Industries Ltd.

Key Drivers of Market Growth:

  • Innovations in Surgery: Advancements in surgical technology, particularly with minimally invasive glaucoma surgeries (MIGS), are transforming the glaucoma therapeutics market. MIGS offers safer, less complicated procedures with quicker recovery times. Innovations in surgical instruments, such as micro-stents and drainage systems, enhance surgical effectiveness, boosting patient outcomes and market growth.
  • Rising Availability of Generic Drugs: The growing availability of generic glaucoma medications is improving access to affordable treatments. Generic versions of popular drugs offer effective alternatives at lower costs, making glaucoma care more accessible, especially for patients with financial constraints.
  • Gene Therapy Innovations in Glaucoma: Advancements in gene therapy are providing innovative approaches to glaucoma treatment by targeting its root causes. These therapies focus on protecting retinal ganglion cells, improving mitochondrial function, and reducing intraocular pressure, offering a promising alternative to traditional treatments with potential long-term benefits and fewer side effects.
  • Increasing Aging Population: The global rise in the elderly population is increasing the prevalence of glaucoma, as older individuals are more susceptible to the condition. This demographic shift is driving the demand for effective diagnostics, treatments, and long-term management strategies, prompting greater investment in age-specific therapeutic solutions.
  • Growing Awareness: Raising awareness about glaucoma is essential for market growth, as it encourages early detection through routine eye exams. Increased awareness through health campaigns and accessible information are catalyzing the demand for diagnostics, treatments, and surgeries, promoting proactive healthcare and boosting the adoption of effective glaucoma therapies.
  • Advancements in Drug Delivery Systems: Innovative drug delivery systems like sustained-release implants, punctal plugs, and injectables are revolutionizing glaucoma treatment by providing longer-lasting effects compared to traditional eye drops. These advancements enhance patient compliance, improve comfort, and ensure consistent therapeutic outcomes, driving the demand for more sophisticated, effective glaucoma therapies.

Future Outlook:

  • Strong Growth Outlook: The glaucoma therapeutics market is experiencing strong growth due to rising prevalence of the condition, aging populations, increasing awareness, and advancements in treatment options. Innovative drug therapies, minimally invasive surgeries, and improved diagnostic technologies are supporting the market expansion and greater patient access to effective treatments.
  • Market Evolution: The glaucoma therapeutics market is evolving with advancements in drug formulations, minimally invasive surgeries, and personalized treatments. Increased research into neuroprotection and combination therapies, along with a growing focus on early detection, is shaping the future landscape, offering more effective and tailored solutions for patients.

Glaucoma ranks among the top causes of permanent blindness globally, with a growing number of individuals being diagnosed annually. The condition typically advances gradually and asymptomatically, complicating early detection and resulting in a larger group of patients needing continuous therapeutic care, thereby broadening the market for glaucoma treatments. Moreover, increasing public awareness initiatives and better education regarding glaucoma are motivating more individuals to undergo screenings, resulting in earlier detections. Earlier intervention leads to an increase in the need for therapeutic treatments as patients aim to control the disease prior to substantial optic nerve damage, supporting the market growth. Besides this, heightened funding from pharmaceutical firms and healthcare institutions in research operations is leading to the identification of new therapies, including neuroprotective treatments focused on maintaining optic nerve health. This emphasis on innovation leads to additional treatment choices, thereby broadening the market offerings and providing patients with renewed optimism for effectively managing glaucoma.

Glaucoma Therapeutics Market Trends/Drivers:

Advancements in Surgical Procedures

Advancements in surgical technology are influencing the glaucoma therapeutics market, especially with the emergence of minimally invasive glaucoma surgeries (MIGS). MIGS is revolutionizing the treatment of glaucoma by providing safer alternatives with reduced complications, quicker recovery periods, and simpler procedures in contrast to conventional surgeries. This advancement provides surgeons with additional treatment options while reducing risks and discomfort for patients. Moreover, developments in surgical instruments, including micro-stents and innovative drainage systems, are improving the effectiveness of glaucoma surgeries. A significant instance of innovation is the 2025 introduction of Alcon's Voyager(TM) DSLT in the US, the initial fully automated Direct Selective Laser Trabeculoplasty apparatus. This instrument streamlines the SLT process by providing 120 laser pulses without requiring a gonio lens or manual targeting, enhancing accuracy and minimizing procedural intricacy. These technological innovations enhance trust in surgical procedures, boosting market expansion and enhancing treatment results.

Growth of Generic Drugs

The increasing availability of generic glaucoma drugs is providing more access to cost-effective therapies. Generic forms of well-known glaucoma medications, like prostaglandin analogs, offer an economical substitute to name-brand treatments while maintaining their effectiveness. This trend is essential for increasing access to treatment, especially for patients who might face financial limitations or restrictions in insurance coverage. Generic medications contribute to lower healthcare expenses while allowing a wider patient demographic to gain access to effective treatments for glaucoma. With the rise of pharmaceutical companies launching generic versions of well-known medications, competition intensifies, leading to lower prices and broader market access. In 2024, Glenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z-Travoprost ophthalmic solution 0.004%-for treating glaucoma and ocular hypertension. The product is bioequivalent to Sandoz's reference drug and expands Glenmark's ophthalmic portfolio. Travatan Z recorded $66.2 million in annual U.S. sales as of September 2024.

Advancements in Gene Therapy

Recent advancements in gene therapy are providing novel, creative methods for addressing the condition. Scientists are investigating gene therapies aimed at addressing the root causes of glaucoma, such as the protection of retinal ganglion cells and the improvement of mitochondrial functions. These treatments, which involve introducing particular genes to the eye, seek to reduce intraocular pressure while also protecting optic nerve integrity and enhancing the overall function of vision-related cells. With the advancement of gene therapy in clinical trials, it emerges as a hopeful substitute for conventional treatments and may provide lasting advantages with reduced side effects. The creation of these advanced treatments is drawing considerable investment and focus, driving market expansion by offering patients more precise, efficient choices for controlling glaucoma. In 2024, Trinity College Dublin researchers announced a breakthrough gene therapy for glaucoma that protects retinal ganglion cells and enhances mitochondrial function. The therapy, using an AAV-delivered eNdi1 gene, improved vision-related cell performance in animal and human models. A spinout, Vzarii Therapeutics, was formed to advance it toward clinical trials.

Glaucoma Therapeutics Market Growth Drivers:

Growing Geriatric Population

The increasing elderly population worldwide, especially in advanced and swiftly developing nations, is leading to a significant rise in glaucoma cases. The World Health Organization (WHO) estimates that by 2030, one in every six individuals globally will be 60 years or older, a figure anticipated to double by 2050, hitting 2.1 billion. This demographic change is expanding the number of patients vulnerable to glaucoma, leading to a growing need for effective diagnostic methods, treatment alternatives, and continuous management approaches. Senior individuals are more vulnerable to long-term ailments such as glaucoma, which frequently necessitates ongoing treatment to avert vision impairment. Therefore, the rising number of elderly individuals is driving the demand for new treatments, including both medical and surgical options. This trend is encouraging investment in research operations to formulate customized therapies that meet the unique requirements of elderly patients, further bolstering the market growth.

Rising Awareness and Early Diagnosis

Raising awareness regarding glaucoma is crucial for stimulating the expansion of the glaucoma therapeutics market. Health campaigns, efforts by eye-care organizations, and greater information accessibility are all helping to raise awareness about the condition. With an increasing number of people recognizing the significance of early detection, there is a rise in the demand for routine eye examinations, especially among high-risk groups. Early diagnosis allows for timely intervention, reducing the risk of irreversible vision loss and ensuring better treatment outcomes. In 2024, AbbVie India and Sightsavers India initiated a 15-month campaign to raise awareness about glaucoma, focusing on people aged 40 and older. The initiative featured screening camps, online outreach, and educational programs to encourage early diagnosis and treatment. This shift towards proactive healthcare leads to higher demand for glaucoma medications, diagnostic tools, and surgical treatments. As a result, greater awareness is directly driving the adoption of glaucoma therapies.

Advancements in Drug Delivery Systems

Innovations, such as sustained-release implants, punctal plugs, and injectable formulations, are changing how glaucoma treatments are delivered. These innovative systems offer a more enduring effect than conventional eye drops, which necessitate regular application, frequently resulting in insufficient patient adherence. Sustained-release systems, for instance, can provide medication for weeks or even months, minimizing the necessity for daily administration and enhancing treatment compliance. This not only improves patient comfort but also guarantees uniform therapeutic outcomes, ultimately resulting in superior management of intraocular pressure. The heightened emphasis on enhancing drug delivery systems is catalyzing the demand for more sophisticated glaucoma therapies. In 2024, Ripple Therapeutics announced a collaboration with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral implant for reducing intraocular pressure in glaucoma. Ripple will handle preclinical development, while AbbVie will lead clinical trials and commercialization. The implant allowed repeat dosing without polymers or excipients, reducing inflammation risk.

Glaucoma Therapeutics Industry Segmentation:

Breakup by Drug Class:

  • Prostaglandin Analogs
  • Beta Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

Prostaglandin analogs represents the largest market segment

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

Open angle glaucoma represents the largest market segment

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving glaucoma therapeutics market demand. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgery Centers
  • Others

Hospitals accounts for the majority of the market share

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The glaucoma therapeutics market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel glaucoma therapeutics market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies, thereby offering a favorable glaucoma therapeutics market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Aerie Pharmaceuticals Inc.
  • Allergan Plc
  • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
  • Inotek Pharmaceuticals Corp.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.
  • SIFI S.p.A
  • Teva Pharmaceutical Industries Ltd

Key Questions Answered in This Report

  • 1.How big is the global glaucoma therapeutics market?
  • 2.What is the expected growth rate of the global glaucoma therapeutics market during 2026-2034?
  • 3.What are the key factors driving the global glaucoma therapeutics market?
  • 4.What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5.What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6.What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7.What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8.What are the key regions in the global glaucoma therapeutics market?
  • 9.Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2025
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players